NEFROTEIN Ketoanalogues / Essential Amino Acids Film-Coated Tablet 1's
RXDRUG-DRP-6051-15-1pc
Discreet Packaging
FDA-registered Products
FDA-licensed Pharmacies
Indications/Uses
For prevention and therapy of damages due to faulty or deficient protein metabolism in chronic renal insufficiency in connection with limited protein in food of 40 g per day (for adults) and less; i.e. generally in patients with a glomerular filtration rate (GFR) below 25 mL/min.
Dosage/Direction for Use
For oral use.
Four to eight tablets, three times a day.
1 tablet/5 kg body weight per day.
Should be taken with food (Swallow whole, do not chew/crush).
Four to eight tablets, three times a day.
1 tablet/5 kg body weight per day.
Should be taken with food (Swallow whole, do not chew/crush).
Administration
Should be taken with food: Swallow whole, do not chew/crush.
Contraindications
Allergy and hypersensitivity to any content of this drug.
Hypercalcemia.
Disturbed amino acid metabolism.
Caution use for patients with phenylketonuria.
Hypercalcemia.
Disturbed amino acid metabolism.
Caution use for patients with phenylketonuria.
Warnings
Ketoanalogues + Essential amino acids (Nefrotein) contains phenylalanine, it should be used with caution in phenylketonuric patients.
Special Precautions
Ketoanalogues + Essential amino acids (Nefrotein) should be taken during meals to allow proper absorption and metabolism into the corresponding amino acids. The serum calcium level should be monitored regularly. Ensure sufficient supply with calories.
Use In Pregnancy & Lactation
No experience has been made so far with the administration of Ketoanalogues + Essential amino acids (Nefrotein) during pregnancy and lactation.
Adverse Reactions
Hypercalcemia may develop in this case, it is recommended to decrease vitamin D intake.
If the hypercalcemia persists, reduce the dosage of Ketoanalogues + Essential amino acids (Nefrotein) as well as any source of calcium.
If the hypercalcemia persists, reduce the dosage of Ketoanalogues + Essential amino acids (Nefrotein) as well as any source of calcium.
Drug Interactions
The simultaneous administration of medicaments containing calcium (e.g. acetolyte) may lead to pathological increases of the serum calcium level or intensification.
As the uraemic symptoms improve under Ketoanalogues + Essential amino acids (Nefrotein), a possible administration of aluminum hydroxide should be reduced. Pay attention to a reduction of serum phosphate. In order not to interfere with absorption, do not take drugs together with Ketoanalogues + Essential amino acids (Nefrotein) that form sparingly soluble compounds with calcium (e.g. tetracyclines, quinolone e.g. ciprofloxacin and norfloxacin, iron-, fluoride- and estramustin-containing drugs). Between the intake of Ketoanalogues + Essential amino acids (Nefrotein) and drugs from the mentioned categories, a period of at least 2 hours should pass. The susceptibility towards heart/cardiac-active glycosides and hence also the risk of arrhythmia increases with the rise of blood calcium concentration.
As the uraemic symptoms improve under Ketoanalogues + Essential amino acids (Nefrotein), a possible administration of aluminum hydroxide should be reduced. Pay attention to a reduction of serum phosphate. In order not to interfere with absorption, do not take drugs together with Ketoanalogues + Essential amino acids (Nefrotein) that form sparingly soluble compounds with calcium (e.g. tetracyclines, quinolone e.g. ciprofloxacin and norfloxacin, iron-, fluoride- and estramustin-containing drugs). Between the intake of Ketoanalogues + Essential amino acids (Nefrotein) and drugs from the mentioned categories, a period of at least 2 hours should pass. The susceptibility towards heart/cardiac-active glycosides and hence also the risk of arrhythmia increases with the rise of blood calcium concentration.
Storage
Store at temperatures not exceeding 30°C. Protect from light.
Action
Pharmacology: Therapeutic Action: Normalizes metabolic process, promotes recycling product exchange. Reduces ion concentration of potassium, magnesium and phosphate.
Pharmacokinetics: In normal individuals, there is an increase in plasma level of ketoanalogues, 10 minutes after oral ingestion. These levels reach values that are approximately 5 times higher than the initial level. Peak levels are reached within 20-60 min, and normal levels are reached again after 90 min. Gastrointestinal absorption is thus very rapid. In the plasma, a simultaneous increase in levels of the ketoanalogue and the corresponding amino acid show that transamination of the ketoanalogues is very rapid. Due to the natural pathways of disposal of α-ketonic acids in the organism, it is probable that exogenous intakes are very rapidly integrated into metabolic cycles. Ketoacids follow the same catabolic pathways as the classical amino acids.
Pharmacokinetics: In normal individuals, there is an increase in plasma level of ketoanalogues, 10 minutes after oral ingestion. These levels reach values that are approximately 5 times higher than the initial level. Peak levels are reached within 20-60 min, and normal levels are reached again after 90 min. Gastrointestinal absorption is thus very rapid. In the plasma, a simultaneous increase in levels of the ketoanalogue and the corresponding amino acid show that transamination of the ketoanalogues is very rapid. Due to the natural pathways of disposal of α-ketonic acids in the organism, it is probable that exogenous intakes are very rapidly integrated into metabolic cycles. Ketoacids follow the same catabolic pathways as the classical amino acids.
MedsGo Class
Other Drugs Acting on the Genito-Urinary System
Features
Brand
Nefrotein
Full Details
Dosage Strength
Calcium-4-methyl-2-oxo-valerate 101 mg Calcium-3-methyl-2-oxo-butyrate 86 mg Calcium-2-oxo-2-phenylpropionate 68 mg Calcium-3-methyl-2-oxo-valerate 67 mg Calcium-DL-2-hydroxy-4-(methylthio) butyrate 59 mg L-Lysine Acetate 105 mg L-Threonine 53 mg L-Histid
Drug Ingredients
- Amino Acid
- Ketoanalogues
Drug Packaging
Film-Coated Tablet 1's
Generic Name
Amino Acid / Ketoanalogues
Dosage Form
Film-Coated Tablet
Registration Number
DRP-6051-15
Drug Classification
Prescription Drug (RX)
Please sign in so that we can notify you about a reply